机器学习预测乳腺癌新辅助治疗后炎症代谢状态改变的模型评价

吴其蓁, 刘启明, 柴烨子, 陶政宇, 王依楠, 郭欣宁, 姜萌, 卜军

Evaluation of machine learning prediction of altered inflammatory metabolic state after neoadjuvant therapy for breast cancer

WU Qizhen, LIU Qiming, CHAI Yezi, TAO Zhengyu, WANG Yinan, GUO Xinning, JIANG Meng, PU Jun

表1 乳腺癌新辅助治疗前及新辅助治疗后患者所有特征变量信息

Tab 1 All feature variable information of patients with breast cancer before and after neoadjuvant therapy

Indicator All (n=232) Patient before neoadjuvant therapy (n=135) Patient after neoadjuvant therapy (n=97) Demographic parameter Age/year 47.00 (40.00, 55.00) 46.00 (39.00, 54.50) 48.00 (40.00, 56.00) Height/m 1.60 (1.58, 1.65) 1.60 (1.58, 1.65) 1.60 (1.58, 1.65) Weight/kg 60.00 (54.00, 67.78) 59.00 (55.00, 66.25) 60.00 (54.00, 68.00) BMI/ (kg·m-2) 22.87 (21.10, 25.39) 22.66 (21.09, 24.96) 23.10 (21.10, 25.50) Systolic blood pressue/mmHg 122.70±13.65 124.77±13.47 119.81±13.45 Diastolic blood pressure/mmHg 77.15±8.72 77.59±7.84 76.54±9.83 Heart rate/ (beat ·min-1) 78.19±5.56 77.63±5.32 78.96±5.87 Accompanied by lymph node metastasis/n(%) 72 (31.0) 44 (32.6) 28 (28.9) Tumor location/n(%) Left side 113 (48.7) 68 (50.4) 45 (46.4) Right side 116 (50.0) 65 (48.1) 51 (52.6) Bilateral 3 (1.3) 2 (1.5) 1 (1.0) Neoadjuvant treatment/n(%) Paclitaxel+cisplatin 26 (26.8) ‒ 26 (26.8) Paclitaxel+cisplatin+trastuzumab 21 (21.6) ‒ 21 (21.6) Paclitaxel+cisplatin+apatinib 35 (36.1) ‒ 35 (36.1) Paclitaxel+cisplatin+pyrotinib 15 (15.5) ‒ 15 (15.5) Cardiovascular risk factor/n(%) Coronary heart disease 0 (0) 0 (0) 0 (0) Hypertension 52 (22.4) 21 (15.6) 31 (31.0) Type 2 diabetes 14 (6.0) 6 (4.4) 8 (8.2) Hyperlipidemia 26 (11.2) 10 (7.4) 16 (16.5) Smoking 0 (0) 0 (0) 0 (0) Electrocardiographic parameter/n(%) ST-T change 0 (0) 0 (0) 2 (2.0) QTc prolongation 0 (0) 0 (0) 0 (0) Echocardiographic parameter AOD/mm 30.00 (28.00, 32.00) 30.00 (28.00, 32.00) 31.00 (28.00, 32.00) LAD/mm 33.44±4.31 33.30±4.14 33.64±4.54 LVEDD/mm 44.62±3.30 44.66±3.35 44.57±3.24 LVESD/mm 28.00 (27.00, 30.00) 28.00 (27.00, 30.00) 29.00 (27.00, 30.00) IVS/mm 8.00 (7.00, 9.00) 8.00 (7.00, 9.00) 8.00 (7.00, 9.00) LVPWT/mm 8.00 (7.00, 8.00) 8.00 (7.00, 8.00) 8.00 (7.00, 9.00) FS/% 36.00 (34.00, 38.00) 36.00 (34.00, 38.00) 37.00 (35.00, 38.00) EF/% 65.00 (63.00, 68.00) 65.00 (63.00, 68.00) 66.00 (63.00, 69.00) Laboratory examination parameter WBC/ (×109·L-1) 5.11 (4.04, 6.56) 5.65 (4.68, 6.86) 4.44 (3.50, 5.79)① HB/ (g·L-1) 120.00 (105.00, 129.00) 127.00 (120.00, 133.00) 105.00 (97.00, 117.00)① HCT 0.36 (0.32, 0.39) 0.38 (0.36, 0.40) 0.32 (0.29, 0.35)① ST2/ (ng·mL-1) 18.14 (13.83, 24.86) 18.38 (13.75, 25.36) 18.11 (14.25, 24.13) BNP/ (pg·mL-1) 19.00 (12.00, 32.00) 19.00 (12.00, 31.00) 21.00 (15.00, 35.00) NT-proBNP/ (pg·mL-1) 24.04 (10.00, 42.58) 24.42 (10.00, 41.58) 23.95 (10.48, 46.28) TNI/ (ng·mL-1) 0 (0, 0) 0 (0, 0) 0 (0, 0.01) hsCRP/ (mg·L-1) 0.71 (0.32, 1.41) 0.70 (0.32, 1.42) 0.86 (0.34, 1.40) TC/ (mmol·L-1) 4.48 (3.91, 5.16) 4.52 (3.98, 5.24) 4.42 (3.85, 4.99) TAG/ (mmol·L-1) 1.35 (0.86, 2.04) 1.02 (0.74, 1.66) 1.75 (1.27, 2.40)① HDL/ (mmol·L-1) 1.10 (0.87, 1.32) 1.24 (1.04, 1.45) 0.87 (0.75, 1.03)① LDL/ (mmol·L-1) 3.34 (2.82, 3.98) 3.21 (2.76, 3.92) 3.47 (2.94, 4.12) NHDL/ (mmol·L-1) 2.52 (2.16, 3.13) 2.60 (2.21, 3.20) 2.41 (2.05, 2.91)② FPG/ (mmol·L-1) 4.95 (4.74, 5.26) 4.88 (4.69, 5.24) 5.05 (4.83, 5.29)④ GOT/ (mmol·L-1) 20.00 (16.00, 26.00) 17.00 (14.00, 23.00) 22.00 (19.00, 29.75) GPT/ (mmol·L-1) 19.00 (13.00, 29.50) 15.00 (11.00, 27.00) 24.00 (17.00, 34.00) γ-GT/ (mmol·L-1) 21.00 (14.00, 40.00) 18.00 (12.00, 32.00) 33.50 (17.00, 47.00) IL-1β/ (pg·mL-1) 5.00 (5.00, 5.00) 5.00 (5.00, 5.00) 5.00 (5.00, 5.00) IL-2R/ (U·mL-1) 330.00 (270.75, 424.75) 295.00 (249.50, 369.50) 399.00 (322.00, 508.00)① IL-6/ (pg·mL-1) 3.15 (2.21, 4.25) 2.97 (2.12, 3.74) 3.66 (2.68, 4.89)⑤ IL-8/ (pg·mL-1) 11.30 (7.72, 18.95) 13.20 (8.81, 21.10) 9.84 (7.06, 15.20)③ IL-10/ (pg·mL-1) 5.00 (5.00, 5.00) 5.00 (5.00, 5.00) 5.00 (5.00, 5.00) TNF-α/ (pg·mL-1) 6.53 (5.26, 7.86) 6.01 (5.00, 7.02) 7.33 (6.03, 8.60)①